 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Tekmira Releases Positive Interim Phase I Data on Cancer Drug, Unsure on Ebola Drug's Fate
August 16, 2012
Tekmira Releases Positive Interim Phase I Data on Cancer Drug, Unsure on Ebola Drug's Fate
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Alnylam Settlement Money in Hand, Tekmira Plans 'Aggressive' Pipeline Advancement
November 15, 2012 / Gene Silencing News - Tekmira Management Offers Pipeline Update, Reiterates Claim to Disputed Delivery Technology
March 29, 2012 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News - Tekmira Gets DoD Green Light to Test Improved Ebola Drug Formulation
May 9, 2013 / Gene Silencing News - Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News